PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma

Wenli Cui1,*, Mingfu Ma1,*, Shutao Zheng2,3, Zhiping Ma1, Liping Su1 and Wei Zhang1

1Department of Pathology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, PR.China
2Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, PR.China
3State Key Lab Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, PR.China

*These authors have contributed equally to this work

Correspondence to: Wenli Cui, email: cwl860@163.com

Keywords: diffuse large B-cell lymphoma (DLBCL), PTEN, PIK3CA, FISH, prognosis

Received: May 10, 2017 Accepted: July 12, 2017 Published: August 03, 2017

Copyright: Cui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Although it has been known that PIK3CA was amplified and PTEN was deficient on protein level in DLBCL, the clinicopathological significance of PIK3CA and PTEN genetic change on DNA level hasn’t been established. Here, in our present study, to understand the clinical significance of genetic status of PIK3CA and PTEN in DLBCL, fluorescent in-situ hybridization (FISH) was employed to evaluate the genetic change of PIK3CA and PTEN in clinical sample tissues consist of 205 cases. Incidentally, to understand the clinicopathological significance of genetic change of PIK3CA and PTEN, Cross-table analysis was used to analyze the association between genetic change of PIK3CA and PTEN versus clinicopathological variables available to us, including age, gender, size, location, international prognosis index, performance state, B-symptom, clinical stage, Extra nodal site, concentration of lactate dehydrogenase, therapeutic effects, treatment and overall prognosis. It was found that PIK3CA was amplified and PTEN was deficient on DNA level, the percentage of amplification and loss was 12.7% (26/205) and 12.2% (25/205), respectively. Additionally, no significant association was observed between genetic change of PIK3CA and PTEN versus clinicopathological variables available. Nor was the significant correlation found between loss of PTEN versus PIK3CA amplification. Our results suggest that PTEN deficiency and amplification of PIK3CA on DNA level was an event in the pathogenesis of DLBCL.

INTRODUCTION

Diffuse large B cell lymphoma (DLBCL) is one of the most common types of aggressive B cell non-Hodgkin lymphomas [1, 2]. DLBCL is highly prevalent and is a heterogeneous disease that can be subdivided into two main lymphoma categories, that is germinal center B cell-like subtype (GCG) and activated B cell-like subtype (ABC), which differs in the gene expression profiles and clinical outcomes [3]. Despite treatment of DLBCL with standard R-CHOP that appears to be superior to CHOP chemotherapy that can cure some patients [1, 4], there are still, approximately 30%-40% of patients were shown to be going to develop relapsed disease that remains the major cause of the poor survival. Therefore, the important issue is to understand the underlying mechanism why refractory DLBCL occurs to patients [5].

Studies showed that constitutive activation of the PI3K/AKT signaling pathway [6, 7] as well as its inhibitor, phosphatase and tensin homolog (PTEN) [8], in GCB-DLBCL plays a central role in promoting survival and chemotherapy-resistance and represents a rational therapeutic target in relapsed or refractory GCB-DLBCL. Deregulation of the PI3K/AKT pathway by the
inactivation of PTEN, was found in 55% of GCB-DLBCL cases, but only in 14% of non-GCB-DLBCL and worsens prognosis [8]. Thus, the both of PTEN and PI3K/AKT signaling pathway has emerged as promising therapeutic targets for relapsed DLBCL [9]. Some inhibitors [7, 8] of PI3K subunit has been currently evaluated in an ongoing early phase I study as a single-agent in patients with relapsed/refractory DLBCL.

Gene amplification of PIK3CA has been considered to contribute to the pathogenesis of DLBCL and mantle cell lymphoma [10, 11]. In our previous study, we’ve evaluated the amplification status of both catalytic and regulatory subunits of PI3K/AKT signaling pathway on DNA level using NanoString nCounter platform on a basis of 60 cases of clinical samples of DLBCL, finding that copy number variation of PIK3CA subunit was amplified [12]. Nevertheless, as for the copy number variation of PTEN gene in DLBCL on DNA level, it remains unknown that hasn’t been established on account of scarce report [13] available regarding PTEN in DLBCL. Given this, we’ve determined to extend the detection of copy number variation of PTEN as well as PIK3CA on DNA level in larger sample tissues of DLBCL and tried to analyze the clinicopathological significance of genetic variation PTEN and PIK3CA.

RESULTS

PIK3CA was found to be amplified in DLBCL

To understand the genetic alteration of PIK3CA gene in DLBCL, fluorescent in-situ hybridization (FISH) was performed. In our setting, only two green and two red fluorescent signals that can be observed in the nucleus of DLBCL cells that was defined as normal or non-amplified status of PIK3CA, for those whose ratio of red signals to green signal was more than one were defined as amplified PIK3CA (Figure 1). According to the cut-off value we’ve set, among 205 cases we’ve enrolled, only 26 cases whose PIK3CA gene status was found to be amplified. The amplification percentage was 12.7% (26/205), while the reminder was non-amplified whose percentage was 87.3% (179/205).

PTEN was shown to be deficiency in DLBCL

Likewise, to understand the genetic change of PTEN in DLBCL, FISH detection was extended from PIK3CA to PTEN. That is, FISH test for PTEN was carried out in the same sample of DLBCL as PIK3CA did. In this setting, the cut-off value we’ve set was the ratio of red signal (which stands for PTEN) to green signal (centromere probe, used as internal control) less than 1 was defined as PTEN deficiency (Figure 2). Following the cut-off value we’ve set, of 205 cases, PTEN loss occurred to 25 cases whose deficient percentage was 12.2% (25/205).

PIK3CA amplification and PTEN deficiency may be independent of overall prognosis and clinicopathological variables available in our setting

Next, to understand the clinicopathological significance of PIK3CA amplification and PTEN deficiency, we’ve analyzed the correlation using Cross-Table statistical approach between genetic alterations of...
PIK3CA and PTEN versus clinicopathological variables available to us, including age, size, international prognosis index (IPI), performance state (PS), B-symptom, clinical stage and so forth. It was found that there was no significant correlation between PIK3CA amplification and clinicopathological variables (Table 1) available to us, including age (p=0.933), gender (p=0.840), size (p=0.440), location (p=0.117), subtype (p=0.659), international prognosis index (IPI) (p=0.956), performance state (PS), B-symptom (p=0.682), Clinical stage (p=0.298), Extra nodal site (p=0.173), concentration of lactate dehydrogenase (LDH) (p=0.684), therapeutic effects (p=0.552) and treatment (p=0.984). Nor was significant correlation observed for PTEN deficiency (Table 2).

Considering the regulation that has been established between PTEN and PI3K signaling pathway, subsequently we’ve tried to analyze the correlation using Spearman Correlation analysis method between amplification of PIK3CA and PTEN deficiency that were detected in the same cohort. It was observed that there was no significant correlation between amplification of PIK3CA and PTEN deficiency but, notably there was a trend towards the significance (p=0.087). Having understood the clinicopathological significance of PIK3CA amplification and PTEN deficiency, we’ve subsequently explored the prognostic significance of PIK3CA amplification and PTEN deficiency. It was shown that there was no markedly difference of overall prognosis between DLBCL patients with PIK3CA amplification and non-amplification (Figure 3). No significant difference of overall prognosis was observed between DLBCL patients with PTEN deficiency and non-deficiency, either (Figure 4). Despite no significant difference of prognosis was found between PIK3CA amplification and non-amplification, there was the trend existed that patients with PIK3CA amplification seem to have had shorter survival relative to those without PIK3CA amplification. As for PTEN deficiency, even there was no trend at all.

**DISCUSSION**

Although previous studies have reported that the genetic changes of PIK3CA and PTEN occurred in DLBCL, little has been known about the clinicopathological significance of genetic changes of both PIK3CA and PTEN on DNA level in DLBCL. In the present investigation, both amplification of PIK3CA and PTEN loss were shown to have occurred on DNA level with the help of FISH approach in DLBCL. The percentage of amplification of PIK3CA and loss of PTEN was 12.7% (26/205) and 12.2% (25/205), respectively. Moreover, no significant association was observed between copy number variation of PIK3CA and PTEN gene versus clinicopathological variables available to us. Nor was association found with overall prognosis. There was the trend towards statistical significance (p=0.087) in spite of no significant correlation was observed between amplification of PIK3CA versus loss of PTEN on DNA level. Our results suggested that both amplification of PIK3CA and loss of PTEN were events in the pathogenesis of DLBCL.

Earlier studies extensively reported that DLBCL relies on constitutive PI3K signaling to block apoptosis [6-8], indicating the important and translational significance of PI3K/AKT pathway in the clinical therapeutic intervention of DLBCL [9]. Among the
Table 1: The correlation between PIK3CA amplification and clinicopathological variables

|                | Total | PIK3CA amplification (%) | P    |
|----------------|-------|--------------------------|------|
| Age            |       |                          |      |
| ≤60            | 124   | 16 (12.9)                | 0.933|
| >60            | 80    | 10 (12.5)                |      |
| Gender         |       |                          |      |
| male           | 122   | 15 (12.3)                | 0.840|
| female         | 83    | 11 (13.3)                |      |
| Size (diameter, cm) | |      |      |
| ≤10            | 168   | 17 (10.1)                | 0.440|
| >10            | 22    | 4 (18.2)                 |      |
| Location       |       |                          |      |
| extra nodular  | 138   | 14 (10.1)                | 0.117|
| Intra nodular  | 67    | 12 (17.9)                |      |
| Subtype        |       |                          |      |
| GCB            | 110   | 15 (13.6)                | 0.659|
| Non-GCB        | 95    | 11 (11.6)                |      |
| IPI            |       |                          |      |
| 0-1            | 106   | 12 (11.3)                | 0.956|
| 2              | 44    | 6 (13.6)                 |      |
| 3              | 22    | 2 (9.1)                  |      |
| 4-5            | 17    | 2 (11.8)                 |      |
| PS             |       |                          |      |
| <2             | 168   | 22 (13.1)                | 0.398|
| >2             | 33    | 2 (6.1)                  |      |
| B-symptom      |       |                          |      |
| presence       | 100   | 11 (11.0)                | 0.682|
| absence        | 101   | 13 (12.9)                |      |
| Clinical stage |       |                          |      |
| I/II           | 115   | 11 (9.6)                 | 0.298|
| III/IV         | 76    | 11 (14.5)                |      |
| Extra nodal site |     |                          |      |
| ≤2             | 162   | 16 (9.9)                 | 0.173|
| >2             | 29    | 6 (20.7)                 |      |
| LDH (U/L)      |       |                          |      |
| ≤240           | 104   | 13 (12.5)                | 0.684|
| >240           | 85    | 9 (10.6)                 |      |
| Therapeutic effect |     |                          |      |
| CR+PR          | 92    | 11 (12.0)                | 0.552|

(Continued)
| Total | PIK3CA amplification (%) | P       |
|-------|--------------------------|---------|
| PD+SD | 20                       | 4 (20.0)|

**Treatment**

| Treatment | Total | PIK3CA amplification (%) | P       |
|-----------|-------|--------------------------|---------|
| CHOP      | 98    | 12 (12.2)                | 0.984   |
| R-CHOP    | 81    | 10 (12.3)                |         |

**PTEN deficiency**

| Total | PIK3CA amplification (%) | P       |
|-------|--------------------------|---------|
| No    | 180                      | 26 (14.4)| 0.087   |
| Yes   | 25                       | 0 (0)    |         |

GCB stands for germinal center B cell; IPI represents international prognosis index; PS denotes performance status; LDH means lactate dehydrogenase; in therapeutic effect, CR means complete response and PR denotes partial response; while PD and SD which were abbreviated for progressive disease and stable disease, respectively. Among 205 cases of samples we’ve enrolled, there was 1 case whose age was unavailable; 15 cases whose size information was unavailable; 16 cases whose IPI was unavailable; 4 cases whose PS was unavailable; 4 cases whose B-system was unavailable; 14 cases whose clinical stage and ExIn2 were unavailable; 16 cases whose LDH level was unavailable; 93 cases whose therapeutic effect was unavailable; 26 cases whose treatment was unavailable.

**Table 2: The correlation between PTEN deficiency and clinicopathological variables**

| Total | PTEN deficiency (%) | P       |
|-------|---------------------|---------|
| Age   |                     |         |
| ≤60   | 124                 | 14 (11.3)| 0.793   |
| >60   | 80                  | 10 (12.5)|         |

| Gender | Total | PTEN deficiency (%) | P       |
|--------|-------|---------------------|---------|
| male   | 122   | 12 (9.8)            | 0.211   |
| female | 83    | 13 (15.7)           |         |

| Size (diameter, cm) | Total | PTEN deficiency (%) | P       |
|---------------------|-------|---------------------|---------|
| ≤10                 | 168   | 21 (12.5)           | 0.645   |
| >10                 | 22    | 2 (9.1)             |         |

| Location | Total | PTEN deficiency (%) | P       |
|----------|-------|---------------------|---------|
| Extra nodular | 138   | 20 (14.5)           | 0.149   |
| Intra nodular | 67    | 5 (7.5)             |         |

| Type | Total | PTEN deficiency (%) | P       |
|------|-------|---------------------|---------|
| GCB  | 110   | 16 (14.5)           | 0.268   |
| Non-GCB | 95    | 9 (9.5)             |         |

| IPI   | Total | PTEN deficiency (%) | P       |
|-------|-------|---------------------|---------|
| 0-1   | 106   | 14 (13.2)           | 0.065   |
| 2     | 44    | 3 (6.8)             |         |
| 3     | 22    | 1 (4.5)             |         |
| 4     | 17    | 5 (29.4)            |         |

| PS    | Total | PTEN deficiency (%) | P       |
|-------|-------|---------------------|---------|
| <2    | 168   | 18 (10.7)           | 0.226   |

(Continued)
different subunits of PI3K/AKT pathway, by reason of PIK3CA whose hot mutational spots have been established to be linked with carcinogenesis of different tumors, more attention was comparatively given on PIK3CA than other subunits of PI3K/AKT pathway. Consequently, we’ve selected PIK3CA as gene of interest. Actually, our previous study had already established that PIK3CA was found to be amplified in DLBCL with sample size of 60 cases using NanoString nCounter platform, the amplification percentage of which was 17% (10/60) [12]. Here, in our present investigation, we’ve extended the sample size of DLBCL tissue from 60 to 205 cases. Based on which we’ve evaluated the amplification of PIK3CA using FISH method, rather than NanoString nCounter approach employed in our previous study [12]. Notably, no significant association was observed between PIK3CA amplification and clinicopathological variables except for overall prognosis [12], which was partially in agreement with our findings presented here that there was no significant association between PIK3CA amplification and clinicopathological variables, of course including overall prognosis. The discrepancy, in terms of association with prognosis, may be due to the different detection approaches and clinical samples we’ve used. In the case of PIK3CA amplification on DNA level in the context of lymphoma or leukemia, the related literatures were scarce and rather limited, not to mention in DLBCL. Psyrrí A and colleagues detected the genetic change of PIK3CA gene in mantel cell lymphoma using quantitative real-time PCR together with FISH method, showing that

|                | Total | PTEN deficiency (%) | P    |
|----------------|-------|---------------------|------|
| B-symptom      |       |                     |      |
| presence       | 101   | 11 (10.9)           | 0.645|
| absence        | 100   | 13 (13)             |      |
| Clinical stage |       |                     |      |
| I/II           | 115   | 15 (13.0)           | 0.601|
| III/IV         | 76    | 8 (10.5)            |      |
| Extra nodal site |      |                     |      |
| ≤2             | 162   | 18 (11.1)           | 0.350|
| >2             | 29    | 5 (17.2)            |      |
| LDH (U/L)      |       |                     |      |
| ≤240           | 104   | 15 (14.4)           | 0.294|
| >240           | 85    | 8 (9.4)             |      |
| Therapeutic effects |      |                     |      |
| CR+PR          | 92    | 14 (15.2)           | 0.546|
| PD+SD          | 20    | 2 (10.0)            |      |
| Treatment      |       |                     |      |
| CHOP           | 98    | 12 (12.2)           | 0.984|
| R-CHOP         | 81    | 10 (12.3)           |      |
| PIK3CA amplification |     |                     |      |
| No             | 178   | 25 (14.0)           | 0.087|
| Yes            | 26    | 0 (0)               |      |

GCB stands for germinal center B cell; IPI represents international prognosis index; PS denotes performance status; LDH means lactate dehydrogenase; in therapeutic effect, CR means complete response and PR denotes partial response; while PD and SD which were abbreviated for progressive disease and stable disease, respectively. Among 205 cases of samples we’ve enrolled, there was 1 case whose age was unavailable; 15 cases whose size information was unavailable; 16 cases whose IPI was unavailable; 4 cases whose PS was unavailable; 4 cases whose B-system was unavailable; 14 cases whose clinical stage and Exln2 were unavailable; 16 cases whose LDH level was unavailable; 93 cases whose therapeutic effect was unavailable; 26 cases whose treatment was unavailable.
amplification of PIK3CA was frequent in both mantle cell lymphoma tissues (15/22, 68%) as well as its derived cell lines. Unfortunately, they failed to analyze the clinicopathological correlation of gain of PIK3CA copy number. Therefore, there is no comparability between ours and findings from Psyrriri A et al [11]. Brown JR et al found using Affymetrix 6.0 SNP array that amplification of PIK3CA occurred on 3q26 in chronic lymphocytic leukemia (CLL) [14]. Nevertheless, they’ve also failed to provide clinicopathological significance of gain of PIK3CA on DNA level in CLL. In this sense, our study was the first time to exhibit the genetic change of PIK3CA subunit on DNA level using FISH technique in DLBCL with larger sample size compared to our own previous study [12]. Furthermore, our present study totally differs from our previous study [12] in that different clinical samples used in addition to different detection method we’ve adopted. However what’s consistent between our two different studies is that, no remarkable association was observed between PIK3CA amplification and clinicopathological variables exception of overall prognosis. In the current study, it should be noted that there was the trend toward the difference of prognosis, despite no significant difference was found. DLBCL patients with gain of PIK3CA gene tend to be shorter survival than those without PIK3CA amplification. Clearly, additional studies with more cases and extended follow-up time are required to further substantiate our findings presented here. As for why PIK3CA was amplified in DLBCL remains to be further studied.

In consideration that there has been paucity of data regarding the clinicopathological significance of the PTEN loss in DLBCL; and that PTEN was the well-established inhibitor of PI3K/AKT signaling pathway [8], we’ve extended the detection of genetic change from PIK3CA to PTEN on DNA level using FISH.

Figure 3: Overall prognosis of PIK3CA amplification in patients with DLBCL. Among the DLBCL samples we’ve enrolled, totaling 205, only 145 cases whose overall prognosis information were available. Of 145 cases, 20 were found to be PIK3CA amplification, whereas the remainder was non-amplification. The cut-off value was set at one that the ratio of red signals to green signals; those whose ratios more than one was defined as PIK3CA amplification, while those whose ratios equal to one were non-amplification. Log-Rank test was used to analyze the statistical difference of overall prognosis between patients with PIK3CA amplification and those with non-amplification.
approach. Our results obtained showed that no remarkable association was observed between PTEN loss on DNA level and clinicopathological variables available to us including overall prognosis, either. Prior numerous studies extensively reported that PTEN deficiency in cancer has been linked with advanced disease, chemotherapy resistance and poor survival [15, 16]. Nevertheless, no significant association was found between loss of PTEN versus overall prognosis in the current study. Our finding was fundamentally in line with the study by Liu YY and associates showing that PTEN protein loss was not associated with patient’s clinical outcome [17], indicating that PTEN may play little prognostic role for patients with DLBCL. In terms of detection level, The vast majority of reports available related to the loss of PTEN in DLBCL, in which PTEN deficiency was commonly determined using immunohistochemistry [13, 17, 18] or western-blot [8] on protein level, which was distinctively different from our current study where PTEN deficiency was evaluated using FISH method on DNA level. Therefore, the difference in detection method could account for the discrepancy of prognostic analysis between the current study and those reporting that PTEN deficiency was markedly associated with inferior prognosis in DLBCL [15]. Given that PTEN was the negative regulator of PI3K/AKT pathway, we’ve also analyzed the correlation between loss of PTEN and PIK3CA amplification. It was observed that there was inversed but not significant correlation, which was in agreement with Pfeifer M et al’s report [8] reporting that in GCB DLBCL, the PTEN status was inversely correlated with activation of the PI3K/AKT pathway in both DLBCL cell lines and primary patient samples. Moreover, based on the evidence of ours and those from previous other studies [8], it stands

Figure 4: Overall prognosis of PTEN deficiency in patients with DLBCL. Among the DLBCL samples we’ve enrolled, totaling 205, only 145 cases whose overall prognosis information were available. Of 145 cases, 18 were found to be PTEN deficiency, the rest was non-deficiency. The cut-off value was set at one that the ratio of red signals to green signals; as long as those whose ratios were less than one it was defined as deficiency, while those whose ratios equal to one were defined as non-deficiency. Log-Rank test was used to analyze the statistical difference of overall prognosis between patients with PTEN deficiency and those with loss.
to reason that it is loss of PTEN on DNA level that may lead to the amplification of PIK3CA gene in DLBCL. As to the regulatory mechanism of PTEN over PIK3CA, it remains to be further investigated. It should be noted that evaluating PTEN loss by IHC or western-blotting as a screen method for PTEN deficiency should be carried out with caution in DLBCL. Loss of PTEN expression by IHC or western-blotting does not equate to PTEN DNA deficiency, as indicated by FISH examination. Nonetheless, if there is PTEN DNA deficiency throughout by FISH detection, one can confidently assume that there will be PTEN loss on protein level. In addition, evaluating for PTEN loss by IHC as a screen for PTEN deletion won’t provide information on the potential chromosomal aberrations that may be detected using FISH technique. Moreover, IHC result of PTEN loss may also be greatly variable with different batches of primary antibodies to PTEN antigen those previous studies employed.

Our analysis based on a larger sample size, making it unlikely that we simply missed an effect due to chance. Despite our study firstly established evidence regarding PTEN deficiency and gain of PIK3CA using FISH method on DNA level in larger sample size, there were still some limitations that deserve to be noted and stressed. A possible explanation for our null association between clinicopathological variables and genetic change of PIK3CA and PTEN is that the cut-off value we’ve set when diagnosing the genetic alterations of PIK3CA and PTEN. Given that there has been factually no agreed standard for evaluation of genetic alterations of PIK3CA and PTEN, therefore, it could be somewhat discretionary to setup the criteria or cut-off value in defining the normal and abnormal genetic change of PIK3CA and PTEN, which may lead to the potential discordance of final findings. In addition, there may be bias in the processing of clinical samples when performing FISH experiment, thereby leading to the potential artifact exists in our scoring of fluorescent signals. Thirdly, given the sensitivity of FISH testing may limit the application of FISH analysis; IHC detection could be therefore complimentary to FISH analysis [19]. Lastly, here we’re not proposing that PIK3CA amplification and PTEN loss are causality of DLBCL but just exhibit the genetic changes of both PIK3CA and PTEN were events in the pathogenesis of DLBCL. Consequently, interpretation of our results should be approached with caution that warrants further confirmation in different cohorts.

Taken together, our study showed the status of amplification of PIK3CA and loss of PTEN in DLBCL on DNA level, observing that no significant association was found between genetic changes of PIK3CA and PTEN versus clinicopathological variables available to us, including overall prognosis, suggesting that amplification of PIK3CA and loss of PTEN was an event in the pathogenesis of DLBCL.

**MATERIALS AND METHODS**

**Clinical samples**

The study was approved by the Medical Ethic Committee of the First Affiliated Hospital of Xinjiang Medical University. Formalin-fixed and paraffin-embedded clinical samples of DLBCL, totaling 205, were enrolled in the department of pathology. The corresponding clinicopathological information was retrieved in Hospital Information System (HIS) including age, gender, size, location, subtype, international prognosis index (IPI), performance status (PS), B-symptom, Clinical stage, Extra nodal site, concentration of lactate dehydrogenase (LDH), therapeutic effects, treatment and overall prognosis. It should be noted that not all the case enrolled whose corresponding clinicopathological information were available. Among 205 cases, there was 1 case whose age was unavailable; 15 cases whose size information was unavailable; 16 cases whose IPI was unavailable; 4 cases whose PS was unavailable; 4 cases whose B-system was unavailable; 14 cases whose clinical stage and Exln2 were unavailable; 16 cases whose LDH level was unavailable; 93 cases whose therapeutic effect was unavailable; 26 cases whose treatment was unavailable; 60 cases whose overall prognosis was unavailable. Diagnoses were histopathologically confirmed and reviewed by two separate clinical pathologists (Zhiping Ma and Mingfu Ma) on the basis of the 2008 World Health Organization (WHO) Classification. Written informed consent was obtained from each participant involved prior to undergoing biopsy.

**Fluorescent in-situ hybridization (FISH)**

Fluorescence in situ hybridization (FISH) were performed to detect the genetic alterations of PIK3CA and PTEN using dual color probe containing a centromeric probe for chromosome 3 (CEN3, spectrum green) and PIK3CA probe located at 3q26 (PIK3CA, spectrum red) (ZytoLight SPEC PIK3CA/CEN 3 Dual Color Probe, Catalogue number: Z-2140-200, ZytoVision, German) or dual color probe containing a centromere probe for chromosome 10 (CEN10, spectrum green) and PTEN probe at 10q23 (PTEN, spectrum red) (Zytolight, SPEC PTEN/CEN 10 Dual Color Probe, Catalogue number: Z-2078-200, ZytoVision, German). Briefly, The DLBCL tissue microarray was de-paraffinized, air-dried and dehydrated in gradient ethanol, followed by denaturation for 5 min at 74 in 70% formamid 2×SSC solution. Hybridization was performed overnight at 37°C in a humidified chamber. Slides were subsequently washed and counterstained with 0.2μmol/L 4’-6-diamidino-2-phenylindole (DAPI) in antifade solution. Stained slides were manually interpreted with fluorescence microscope (Olympus, Japan), and the predominant FISH signal
numbers were recorded in each tissue spot. For each of the cases, a minimum of 100 nonoverlapping cancer cells were evaluated for each case, totaling 100–200 cells per case. Only if ≥90% of cells demonstrated sufficient signal was the slide considered to be qualified for counting. PIK3CA amplification was considered to be present if ≥10% of nuclei [20] contained multiple PIK3CA signals and the PIK3CA /CEP3 ratio was >1 [21]. Likewise, PTEN deficiency was defined as ≥10% of nuclei contained multiple PTEN signals and the PTEN /CEP10 ratio was <1, whereas the ratio was 1 was considered the wild-type [21].

Statistical analysis
Survival analysis was performed using Kaplan–Meier survival curve with Log-Rank test. The Fisher’s exact or χ2 test was used for statistical analysis of association between genetic alterations versus clinicopathological variables. The statistical analysis was performed using SPSS 17.0 software package version (Chicago, IL, USA). P value was less than 0.05 was considered to be statistically significant compared to control.

ACKNOWLEDGMENTS
The study was supported by Natural Science Foundation of China (No.81560035) and Science and technology talents training project of Xinjiang Uyghur Autonomous Region (qn2015bs011), Natural Science Foundation of Xinjiang Uyghur Autonomous Region (2014211C032), and Post-doctor project of Xinjiang Medical University.

CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.

REFERENCES
1. Hong JY, Suh C, Kim WS. Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Res. 2016; 5.
2. Camici R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015; 14: 207.
3. Sandoval-Sus JD, Chavez J, Dalia S. A new therapeutic era in GCB and ABC diffuse large B-cell lymphoma molecular subtypes: a cell of origin-driven review. Curr Cancer Drug Targets. 2016; 16: 305-22.
4. Jia J, Li W, Zheng Y. Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: a case report and review of literature. Medicine (Baltimore). 2017; 96: e6161.
5. Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res. 2013; 19: 1660-9.
6. Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol. 2013; 92: 1351-8.
7. Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014; 19: 14304-15.
8. Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dirmhofer S, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013; 110: 12420-5.
9. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgama U, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS. Role of phosphatidylinositol 3’-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006; 108: 4178-86.
10. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Ofišt K, Ihanwar SC, Chaganti RS. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 1998; 92: 234-40.
11. Pysrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, Argyriou P, Pectasides D, Harhalakis N, Pappa V, Koliaklexi A, Economopoulou C, Kontsioxi F. Phosphatidylinositol 3’-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009; 15: 5724-32.
12. Cui W, Cai Y, Wang W, Liu Z, Wei P, Bi R, Chen W, Sun M, Zhou X. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. J Transl Med. 2014; 12: 10.
13. Ma Y, Zhang P, Gao Y, Fan H, Zhang M, Wu J. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. Int J Clin Exp Pathol. 2015; 8: 14875-84.
14. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, Maccornail L, Wu CJ, Van de Peer Y. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012; 18: 3791-802.
15. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M, Söderberg O, Enblad G, Rosén A, Mustelin T, Jerkeman M, Persson JL, Wingren AG. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma. 2007; 48: 2221-32.
16. Wang X, Huang H, Young KH. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY). 2015; 7: 1032-49. https://doi.org/10.18632/aging.100855.

17. Liu YY, Yao SN, Zhao Y, Yao ZH, Ma J, Xia QX, Fu K, Yang SJ. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma. Leuk Lymphoma. 2010; 51: 1692-8.

18. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, Uddin S, Al-Kuraya K. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia. 2007; 21: 2368-70.

19. Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005; 58: 710-4.

20. Kumar A, Boyle EA, Tokita M, Mikheev AM, Sanger MC, Girard E, Silber JR, Gonzalez-Cuyar LF, Hiatt JB, Adey A, Lee C, Kitzman JO, Born DE. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 2014; 15: 530.

21. Beg S, Siraj AK, Jehan Z, Prabakaran S, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS. PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. Br J Cancer. 2015; 112: 1938-43.